Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare Event
Author:
Publisher
Hindawi Limited
Subject
Oncology,Surgery,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1524-4741.2007.00396.x/fullpdf
Reference53 articles.
1. Targeted Therapy in Breast Cancer
2. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast
3. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study
4. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinomain situ of the breast
5. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness
Cited by 83 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment;Biomedicines;2023-10-07
2. Assessment of HER2 in Gastric-Type Endocervical Adenocarcinoma and its Prognostic Significance;Modern Pathology;2023-06
3. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept;Cancers;2023-05-09
4. Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression;Archives of Pathology & Laboratory Medicine;2023-04-04
5. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma;Pathology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3